<DOC>
	<DOCNO>NCT00255008</DOCNO>
	<brief_summary>This multicenter clinical trial design compare efficacy 48 week therapy pegylated ( PEG ) -Interferon/ribavirin Southeastern Asian patient genotype 1 chronic hepatitis C 48 week therapy PEG-Interferon/ribavirin Caucasian patient genotype 1 chronic hepatitis C. This study also design provide randomize comparison 24 week versus 48 week therapy PEG-Interferon/ribavirin Southeastern Asian patient genotypes 6-9 . The primary endpoint sustain virologic response , define negative hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) serum 24 week therapy completion .</brief_summary>
	<brief_title>Peg-Intron Rebetol Therapy Treatment Naive Hepatitis C Patients : A Comparison Race Genotype Treatment Outcome ( Study P04212 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Comply current Australian Schedule Pharmaceutical Benefits S100 eligibility criterion . Able give write informed consent adhere study visit schedule . South East Asian ethnicity ( except Caucasian Gt1/1b comparator arm ) i.e . bear Vietnam , Cambodia , Laos , Thailand , Hong Kong , China parent born country . Genotype 1 , 1a , 1b , 6 , 6a , 6b , 7 , 8 , 9 , classify INNOLiPA assay . Hemoglobin &gt; =120 g/L ( female ) , &gt; =130 g/L ( male ) . Platelet count &gt; =100 x 10^9/L . Neutrophil count &gt; =1.5 x 10^9/L . Negative pregnancy test female . Thyroid stimulate hormone ( TSH ) within normal limit . Participation investigational drug program within 30 day Screening Visit . Human immunodeficiency virus ( HIV ) antibody positive hepatitis B surface antigen ( HBsAg ) positive . Genotype 2 , 3 , 4 , 5 , classify INNOLiPA assay . Non South East Asian ethnicity ( unless recruit Caucasian GT1 comparator arm ) . Evidence liver disease due disorder ( e.g. , hemachromatosis , Wilson 's disease ) . Ongoing drug alcohol abuse opinion investigator would jeopardize patient 's ability comply study requirement . Inability comply study requirement reason . Decompensated cirrhosis ( Ascites , history encephalopathy bleeding varix , serum albumin &lt; 35 g/L , prothrombin time ( PT ) prolong great 3 sec ) . Present prior history severe psychiatric disease require hospitalization medication . History severe seizure disorder . History autoimmune disorder ( e.g. , rheumatoid arthritis , inflammatory bowel disease , immune thrombocytopenic purpura , systemic lupus erythematosus , mixed connective tissue disease , psoriasis , optic neuritis ) . Poorly control thyroid disease . Creatinine clearance &lt; 50 mL/min . Severe cardiovascular disease . Hepatocellular cancer . Clinically significant ophthalmologic disorder . Hemoglobinopathies ( e.g. , thalassemia , sicklecell anemia ) . Treatment recent treatment immunosuppressive agent ( exclude shortterm corticosteroid withdrawal ) , immunosuppressed transplant recipient scheme .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>pegylated interferon alfa-2b</keyword>
	<keyword>ribavirin</keyword>
	<keyword>Asia</keyword>
</DOC>